M J Burke

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. ncbi Survival differences between adolescents/young adults and children with B precursor acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation
    Michael J Burke
    Division of Pediatric Hematology Oncology, University of Minnesota, Amplatz Children s Hospital, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 19:138-42. 2013
  2. ncbi Treatment of relapsed acute lymphoblastic leukemia: approaches used by pediatric oncologists and bone marrow transplant physicians
    Michael J Burke
    Division of Pediatric Hematology Oncology, University of Minnesota, Minneapolis, MN, USA
    Pediatr Blood Cancer 58:840-5. 2012
  3. ncbi Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival
    M J Burke
    Division of Hematology Oncology Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 43:107-13. 2009
  4. ncbi Treatment of a CNS relapse while on therapy for Burkitt lymphoma
    Michael J Burke
    Division of Pediatric Hematology Oncology Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota, USA
    Pediatr Blood Cancer 52:290-2. 2009
  5. ncbi Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients
    M J Burke
    University of Minnesota, Minneapolis, 55455, USA
    Bone Marrow Transplant 44:169-74. 2009
  6. ncbi The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era
    Michael J Burke
    Division of Pediatric Hematology Oncology Blood and Marrow Transplantation, University of Minnesota Children s Hospital Fairview, Minneapolis, Minnesota 55455, USA
    Pediatr Blood Cancer 53:992-5. 2009
  7. ncbi Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL)
    Michael J Burke
    Division of Pediatric Hematology Oncology Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Pediatr Blood Cancer 53:1289-94. 2009
  8. ncbi Allogeneic hematopoietic cell transplantation outcomes for children with B-precursor acute lymphoblastic leukemia and early or late BM relapse
    J C Beck
    Division of Pediatric Hematology Oncology Bone and Marrow Transplantation, University of Minnesota, Minneapolis, MN 55455 USA
    Bone Marrow Transplant 46:950-5. 2011
  9. ncbi Lower leukemia relapse in pediatric patients with pulmonary cytolytic thrombi following allogeneic transplant
    A R Smith
    Pediatric Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 46:368-71. 2011

Detail Information

Publications9

  1. ncbi Survival differences between adolescents/young adults and children with B precursor acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation
    Michael J Burke
    Division of Pediatric Hematology Oncology, University of Minnesota, Amplatz Children s Hospital, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 19:138-42. 2013
    ..Further improvements in peritransplantation care are needed to limit complications in AYA patients...
  2. ncbi Treatment of relapsed acute lymphoblastic leukemia: approaches used by pediatric oncologists and bone marrow transplant physicians
    Michael J Burke
    Division of Pediatric Hematology Oncology, University of Minnesota, Minneapolis, MN, USA
    Pediatr Blood Cancer 58:840-5. 2012
    ..Management of relapsed B-precursor acute lymphoblastic leukemia (ALL) is challenging and varied. We hypothesized that treatment approaches differ between pediatric oncologists and bone marrow transplant (BMT) physicians...
  3. ncbi Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival
    M J Burke
    Division of Hematology Oncology Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 43:107-13. 2009
    ..We suggest that imatinib be included in the peri-transplant management of all patients with Ph+ ALL...
  4. ncbi Treatment of a CNS relapse while on therapy for Burkitt lymphoma
    Michael J Burke
    Division of Pediatric Hematology Oncology Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota, USA
    Pediatr Blood Cancer 52:290-2. 2009
    ..Our experience shows both the feasibility and efficacy of such an approach in a patient with an otherwise very poor prognosis...
  5. ncbi Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients
    M J Burke
    University of Minnesota, Minneapolis, 55455, USA
    Bone Marrow Transplant 44:169-74. 2009
    ..44). Thus, patients treated with imatinib either before or after myeloablative allo-HCT had no increase in cardiac toxicity...
  6. ncbi The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era
    Michael J Burke
    Division of Pediatric Hematology Oncology Blood and Marrow Transplantation, University of Minnesota Children s Hospital Fairview, Minneapolis, Minnesota 55455, USA
    Pediatr Blood Cancer 53:992-5. 2009
    ..As the treatment of Philadelphia positive (Ph+) leukemias in the era of imatinib continues to evolve, the role of allogeneic hematopoietic cell transplantation (allogeneic-HCT) in first remission is becoming more unclear...
  7. ncbi Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL)
    Michael J Burke
    Division of Pediatric Hematology Oncology Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Pediatr Blood Cancer 53:1289-94. 2009
    ..Since the introduction of imatinib into the treatment of this disease, the role of allogeneic HCT is more uncertain...
  8. ncbi Allogeneic hematopoietic cell transplantation outcomes for children with B-precursor acute lymphoblastic leukemia and early or late BM relapse
    J C Beck
    Division of Pediatric Hematology Oncology Bone and Marrow Transplantation, University of Minnesota, Minneapolis, MN 55455 USA
    Bone Marrow Transplant 46:950-5. 2011
    ..04). These results suggest that allo-HCT should be pursued in children after a first marrow relapse, rather than waiting for subsequent recurrence...
  9. ncbi Lower leukemia relapse in pediatric patients with pulmonary cytolytic thrombi following allogeneic transplant
    A R Smith
    Pediatric Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 46:368-71. 2011
    ..02), cGVHD (P=0.01) and development of PCT (P<0.01) were independently associated with less relapse. These data suggest that patients with PCT are at greater risk for GVHD, but at lower risk of leukemia relapse...